Cargando…

Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients

Objective Recently, tenofovir disoproxil fumatate (TDF)-related side effects, such as renal nephrotoxicity and reduction of bone mineral density, have been reported. Consequently, increased switching from fixed-dose tablet TDF and emtricitabine (TDF/FTC) to abacavir and lamivudine (ABC/3TC) has occu...

Descripción completa

Detalles Bibliográficos
Autores principales: Arae, Hirotaka, Tateyama, Masao, Nakamura, Hideta, Tasato, Daisuke, Kami, Kaoru, Miyagi, Kyoko, Maeda, Saori, Uehara, Hitoshi, Moromi, Makiko, Nakamura, Katsunori, Fujita, Jiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216139/
https://www.ncbi.nlm.nih.gov/pubmed/27904105
_version_ 1782491872014368768
author Arae, Hirotaka
Tateyama, Masao
Nakamura, Hideta
Tasato, Daisuke
Kami, Kaoru
Miyagi, Kyoko
Maeda, Saori
Uehara, Hitoshi
Moromi, Makiko
Nakamura, Katsunori
Fujita, Jiro
author_facet Arae, Hirotaka
Tateyama, Masao
Nakamura, Hideta
Tasato, Daisuke
Kami, Kaoru
Miyagi, Kyoko
Maeda, Saori
Uehara, Hitoshi
Moromi, Makiko
Nakamura, Katsunori
Fujita, Jiro
author_sort Arae, Hirotaka
collection PubMed
description Objective Recently, tenofovir disoproxil fumatate (TDF)-related side effects, such as renal nephrotoxicity and reduction of bone mineral density, have been reported. Consequently, increased switching from fixed-dose tablet TDF and emtricitabine (TDF/FTC) to abacavir and lamivudine (ABC/3TC) has occurred. Interestingly, while TDF has a lipid-lowering property, one of the ABC-related side effects is hyperlipidemia. Therefore, such switching could cause lipid elevation. To evaluate the change in lipid levels associated with switching from TDF/FTC to ABC/3TC in virologically-suppressed human immunodeficiency virus (HIV)-infected patients. Methods This is a retrospective, single-center study. We included the HIV-infected patients whose therapy included a drug switch from TDF/FTC to ABC/3TC between September 2009 and December 2012 at Ryukyu University Hospital. The exclusion criteria were HIV-RNA >40 copies/mL on the switching day, and a documented therapy change to a lipid-lowering agent or any other antiretroviral agents within 3 months before or after switching. We compared the low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), and triglyceride (TG) levels before switching to three months after. Results A total of 18 patients met the inclusion criteria. The LDL, HDL, and TC levels significantly increased three months following the switch (p<0.05), with median (interquartile range) values of 17 (7, 32), 6 (2, 13), and 27 (10, 45) mg/dL, respectively. The TG values did not markedly change. Conclusion Switching from TDF/FTC to ABC/3TC resulted in significantly increased LDL, HDL, and TC levels.
format Online
Article
Text
id pubmed-5216139
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-52161392017-01-09 Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients Arae, Hirotaka Tateyama, Masao Nakamura, Hideta Tasato, Daisuke Kami, Kaoru Miyagi, Kyoko Maeda, Saori Uehara, Hitoshi Moromi, Makiko Nakamura, Katsunori Fujita, Jiro Intern Med Original Article Objective Recently, tenofovir disoproxil fumatate (TDF)-related side effects, such as renal nephrotoxicity and reduction of bone mineral density, have been reported. Consequently, increased switching from fixed-dose tablet TDF and emtricitabine (TDF/FTC) to abacavir and lamivudine (ABC/3TC) has occurred. Interestingly, while TDF has a lipid-lowering property, one of the ABC-related side effects is hyperlipidemia. Therefore, such switching could cause lipid elevation. To evaluate the change in lipid levels associated with switching from TDF/FTC to ABC/3TC in virologically-suppressed human immunodeficiency virus (HIV)-infected patients. Methods This is a retrospective, single-center study. We included the HIV-infected patients whose therapy included a drug switch from TDF/FTC to ABC/3TC between September 2009 and December 2012 at Ryukyu University Hospital. The exclusion criteria were HIV-RNA >40 copies/mL on the switching day, and a documented therapy change to a lipid-lowering agent or any other antiretroviral agents within 3 months before or after switching. We compared the low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), and triglyceride (TG) levels before switching to three months after. Results A total of 18 patients met the inclusion criteria. The LDL, HDL, and TC levels significantly increased three months following the switch (p<0.05), with median (interquartile range) values of 17 (7, 32), 6 (2, 13), and 27 (10, 45) mg/dL, respectively. The TG values did not markedly change. Conclusion Switching from TDF/FTC to ABC/3TC resulted in significantly increased LDL, HDL, and TC levels. The Japanese Society of Internal Medicine 2016-12-01 /pmc/articles/PMC5216139/ /pubmed/27904105 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Arae, Hirotaka
Tateyama, Masao
Nakamura, Hideta
Tasato, Daisuke
Kami, Kaoru
Miyagi, Kyoko
Maeda, Saori
Uehara, Hitoshi
Moromi, Makiko
Nakamura, Katsunori
Fujita, Jiro
Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients
title Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients
title_full Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients
title_fullStr Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients
title_full_unstemmed Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients
title_short Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients
title_sort evaluation of the lipid concentrations after switching from antiretroviral drug tenofovir disoproxil fumarate/emtricitabine to abacavir sulfate/lamivudine in virologically-suppressed human immunodeficiency virus-infected patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216139/
https://www.ncbi.nlm.nih.gov/pubmed/27904105
work_keys_str_mv AT araehirotaka evaluationofthelipidconcentrationsafterswitchingfromantiretroviraldrugtenofovirdisoproxilfumarateemtricitabinetoabacavirsulfatelamivudineinvirologicallysuppressedhumanimmunodeficiencyvirusinfectedpatients
AT tateyamamasao evaluationofthelipidconcentrationsafterswitchingfromantiretroviraldrugtenofovirdisoproxilfumarateemtricitabinetoabacavirsulfatelamivudineinvirologicallysuppressedhumanimmunodeficiencyvirusinfectedpatients
AT nakamurahideta evaluationofthelipidconcentrationsafterswitchingfromantiretroviraldrugtenofovirdisoproxilfumarateemtricitabinetoabacavirsulfatelamivudineinvirologicallysuppressedhumanimmunodeficiencyvirusinfectedpatients
AT tasatodaisuke evaluationofthelipidconcentrationsafterswitchingfromantiretroviraldrugtenofovirdisoproxilfumarateemtricitabinetoabacavirsulfatelamivudineinvirologicallysuppressedhumanimmunodeficiencyvirusinfectedpatients
AT kamikaoru evaluationofthelipidconcentrationsafterswitchingfromantiretroviraldrugtenofovirdisoproxilfumarateemtricitabinetoabacavirsulfatelamivudineinvirologicallysuppressedhumanimmunodeficiencyvirusinfectedpatients
AT miyagikyoko evaluationofthelipidconcentrationsafterswitchingfromantiretroviraldrugtenofovirdisoproxilfumarateemtricitabinetoabacavirsulfatelamivudineinvirologicallysuppressedhumanimmunodeficiencyvirusinfectedpatients
AT maedasaori evaluationofthelipidconcentrationsafterswitchingfromantiretroviraldrugtenofovirdisoproxilfumarateemtricitabinetoabacavirsulfatelamivudineinvirologicallysuppressedhumanimmunodeficiencyvirusinfectedpatients
AT ueharahitoshi evaluationofthelipidconcentrationsafterswitchingfromantiretroviraldrugtenofovirdisoproxilfumarateemtricitabinetoabacavirsulfatelamivudineinvirologicallysuppressedhumanimmunodeficiencyvirusinfectedpatients
AT moromimakiko evaluationofthelipidconcentrationsafterswitchingfromantiretroviraldrugtenofovirdisoproxilfumarateemtricitabinetoabacavirsulfatelamivudineinvirologicallysuppressedhumanimmunodeficiencyvirusinfectedpatients
AT nakamurakatsunori evaluationofthelipidconcentrationsafterswitchingfromantiretroviraldrugtenofovirdisoproxilfumarateemtricitabinetoabacavirsulfatelamivudineinvirologicallysuppressedhumanimmunodeficiencyvirusinfectedpatients
AT fujitajiro evaluationofthelipidconcentrationsafterswitchingfromantiretroviraldrugtenofovirdisoproxilfumarateemtricitabinetoabacavirsulfatelamivudineinvirologicallysuppressedhumanimmunodeficiencyvirusinfectedpatients